Kevin Charles Gorman, Director of Xencor XNCR, has filed 1 purchase and 23 sales on the open market. Over the past 12 months that comes to a net sale of $37.9M. The latest trade was on 06/15.

KG

KG

Kevin Charles Gorman

Director

Company

Xencor XNCR

First filing

23/02/02

Trades

69 trades

Buys / sales

1 / 23

12-month net buying

−$37.9M

Last trade

06/15

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
XencorXNCR	Open-market sale10b5-1 plan	06/15	06/17	7,527 sh	$12.31	$92,657.37	−39.8%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	05/19	05/21	245,088 sh	$154.33	$37,824,431.04	−32.4%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	25/08/07	25/08/11	106,322 sh	$126.41	$13,440,164.02	−17.1%
XencorXNCR	Open-market sale10b5-1 plan	25/06/16	25/06/16	3,173 sh	$9.22	$29,255.06	−14.4%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	25/05/27	25/05/29	9,613 sh	$120.38	$1,157,212.94	−1.8%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	25/02/13	25/02/14	5,844 sh2 trades	$116.68avg.	$681,906.24	−1.1%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	25/02/10	25/02/12	2,274 sh	$118.37	$269,173.38	−0.4%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	25/01/31	25/02/04	2,707 sh	$152.92	$413,954.44	−0.5%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	25/01/27	25/01/29	146,105 sh	$149.46	$21,836,853.3	−22.1%
XencorXNCR	Open-market sale	24/09/27	24/10/01	2,654 sh	$20.68	$54,884.72	−24.0%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/02/13	24/02/15	2,832 sh	$133.02	$376,712.64	−0.5%
XencorXNCR	Open-market buy	24/02/13	24/02/15	53 sh	$19.12	$1,013.36	+1.1%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/02/06–24/02/08	24/02/08	5,314 sh2 trades	$138.74avg.	$737,284.3	−1.0%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/01/31	24/02/02	2,707 sh	$140.69	$380,847.83	−0.5%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	24/01/08–24/01/09	24/01/10	167,858 sh2 trades	$133.02avg.	$22,328,489.63	−25.1%
Neurocrine BiosciencesNBIX	Open-market sale10b5-1 plan	23/08/21	23/08/23	9,328 sh	$107.40	$1,001,827.2	−1.8%
Neurocrine BiosciencesNBIX	Open-market sale	23/02/06–23/02/08	23/02/08	29,044 sh4 trades	$102.90avg.	$2,988,687.06	−5.6%
Neurocrine BiosciencesNBIX	Open-market sale	23/01/31	23/02/02	2,707 sh	$110.08	$297,986.56	−0.6%